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ABSTRACT
Introduction: Metabolism of iron is altered in patients infected with chronically 
Hepatitis C. The aim of this study is to compare compare the hepcidin levels in between 
individuais chronically infected with HCV and uninfected individuals. The aim of this 
study is to compare the hepcidin serum levels between individuals chronically infected 
with HCV and uninfected individuals.
Methods: A cross-sectional study evaluating hepcidin serum levels of mono-infected 
HCV (n=29), naive, non-diabetic, non-cirrhotic and non-obese patients by means of 
ELISA, compared to uninfected patients (n=9) with the same characteristics. The degree 
of liver fibrosis, according to the METAVIR scale on liver biopsies, the lipid profile, the 
resistance insulin level, as calculated on HOMA-IR (homeostatic model assessment 
for insulin resistance), the interleukin-6 (IL-6) and the ferritin serum levels were also 
measured.
Results: The levels of hepcidin were significantly lower in HCV patients compared 
to controls (8.4 pg/mL (±4.94) vs. 19.51 pg/mL (±5.51)) with p<0.001. The levels of 
ferritin and hepcidin did not show any relation. There was no difference between 
hepcidin levels in relation to viral genotype, viral load, IL-6 and degrees of fibrosis 
within HCV infected individuals.
Conclusion: It is possible that hepatic iron overload in this population is explained 
by suppressed levels of hepcidin in patients with HCV.
Keywords: Hepcidin; HCV; interleukin-6 (IL-6); mono-infected
Iron is an essential ion for many cellular metabolic processes in the 
human body, participating in processes of hematopoiesis, DNA synthesis and 
mitochondrial respiration. On the other hand, its excess can stimulate cellular 
damage by promoting oxidative stress1,2. This element of homeostasis depends 
primarily on hepcidin, a polypeptide hormone with 25 amino acids synthesized 
in the liver, which controls its absorption, storage and recirculation2,3. Chronic 
hepatitis C virus (HCV) infection is a major global public health problem. 
It is estimated that the RNA virus of the Flaviviridae family and Hepacivirus4-7 
genus chronically infects about 170 million people, and about 20% of these 
will progress to cirrhosis and its consequences8,9. In individuals with HCV, 
30-40% have high iron, ferritin and transferrin saturation serum levels10-12. 
The increased cellular and systemic iron levels have been associated with 
a worse prognosis in these patients11-13. At present, the HCV is a known 
activator of several signaling pathways that cause the production of reactive 
oxygen species (ROS) leading to oxidative stress in both hepatocytes and 
liver macrophages14. The exact mechanisms by which HCV influences the iron 
homeostasis modulation are still unknown and its influence on the production of 
hepcidin remains controversial2. At the molecular level, there is a link between 
hepcidin and ferroportin, a transmembrane protein expressed in enterocytes 
and macrophages, which is responsible for iron efflux. Their association 
culminates with the internalization and degradation of ferroportin, reducing iron 
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entry in the plasma compartment15,16. Factors such 
as iron reserve, hypoxia, anemia and inflammatory 
processes influence this metabolic process15-17, 
therefore we included only non-diabetic and non-
obese patients with low degrees of hepatic fibrosis 
by the METAVIR system (an international validated 
scale for assessing the degree of fibrosis in patients 
with Hepatitis C) to reduce the confounding factors. 
In this study, we compared the hepcidin serum levels 
between individuals chronically infected with HCV 
and uninfected individuals.
METHODS
Patients
This study was approved by the Research Ethics 
Committee of the Institution, and the individuals signed 
the free informed consent form. A cross-sectional 
study was conducted at the Hospital de Clínicas de 
Porto Alegre (HCPA), a tertiary hospital in southern 
Brazil, between March 2011 and December 2013, 
comparing the assessment of liver fibrosis on liver 
biopsies through METAVIR score18, serum hepcidin 
levels, lipid profile, ferritin values of homeostasis 
model for insulin resistance (HOMA-IR), body mass 
index (BMI), serum levels of IL-6, and demographic 
variables among 29 HCV mono-infected patients, 
naïve, with low degrees of hepatic fibrosis score, 
and 9 uninfected patients, aged 18-60. Virus-related 
variables such as viral load and genotype and their 
relation with the expression of hepcidin were also 
analyzed. Patients with clinical, laboratory and 
or histopathological evidence of liver disease not 
associated with HCV, severe chronic diseases, obesity 
(Body Mass Index, BMI ≥30 Kg/m2), excessive alcohol 
consumption in the last six months (up to 40g/day), 
diabetes, and users of corticosteroids and/or other 
immunosuppressant or lipid-lowering drugs were 
excluded. Patients with current malignant disease, 
active opportunistic infections, transplanted, and 
pregnant women were also excluded. In the uninfected 
group were included HCV-uninfected individuals 
aged 18-60, regardless of sex and using the same 
factors of exclusion of infected ones.
Hepcidin and Interleukin-6 quantitation
The hepcidin serum level was performed by 
collecting blood from a peripheral vein (cubital), with 
pre-established fasting for 12 hours.
The blood was centrifuged immediately after 
collection and the serum samples stored at 
-20 °C, then transferred to a -80 °C freezer up to 
hepcidin measurement. The hepcidin levels were 
determined using the ELISA kit for human Hep C 
(Uscn Life Science Inc., Wuhan, China), and all 
samples analyzed in duplicate. The IL-6 serum level 
was determined using the ELISA Kit Human IL-6 
(Invitrogen™, Camarillo, USA) also in duplicate. 
The HOMA-IR dosages of fasting glucose in mg/dL 
were calculated and serum insulin was considered 
in mU/mL. The final value of the HOMA-IR was 
obtained by multiplication between serum insulin by 
fasting glucose divided by the constant 405. Insulin 
resistance was defined as HOMA-IR> 2.7, according 
to the Brazilian threshold19. The viral detection and 
determination of viral load was performed by real-time 
polymerase chain reaction in peripheral blood with 
a detection limit of 43 IU/mL. Genotyping was 
determined by RT-PCR with reverse hybridization 
(Roche™). The METAVIR19,20 score was analyzed 
in samples with 8 or more portal tracts by an expert 
pathologist. The biochemical tests were conducted 
in laboratory routine in the tertiary center and the 
anthropometric measurements using calibrated and 
measured equipment by the Brazil National Institute 
of Metrology, Quality and Technology (INMETRO).
Statistical Analysis
Data were entered into Excel and then exported 
to SPSS version 18.0 for statistical analysis. 
Categorical variables were described as frequencies 
and percentages. Quantitative variables with normal 
distributions were described by mean ± SD and 
those with asymmetric distribution were described 
with the median and interquartile range. Categorical 
variables were compared using Fisher’s exact test. 
Quantitative variables with normal distributions were 
compared between groups by Student’s t test for 
independent samples. Variables with asymmetric 
distribution were compared between groups by 
Mann- Whitney to evaluate the correlation between 
variables; the Pearson correlation coefficient was 
used (we used the normal distribution according to 
the usual range worldwide. Therefore, we use the 
Pearson correlation). Due to the lack of previous 
evidence according to the relationship between ferritin 
and hepcidin, it was obtained a convenience sample 
in a 3 cases: 1 control ratio. A significance level of 
5% was considered for the established comparisons.
RESULTS
Participants included a total of 38 individuals, 
29 patients chronically infected with HCV and 9 uninfected. 
Demographic and clinical characteristics of the individuals 
analyzed did not differ significantly in sex, race, BMI, 
lipid profile (expressed by quantifying the levels of total 
cholesterol and triglycerides), values of HOMA-IR and 
serum ferritin levels. There was a significant difference 
in the age groups having the infected group presented 
a mean age of 46.9 (±7.07) years versus 33.8 (±5.2) 
years (Table 1). The cases had a IL-6 median of 
33.8 pg/mL (interquartile range: 0.01 to 66.5 pg/mL) 
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and the controls 41.6 pg/mL (interquartile range 
23.5 to 75.0 pg/mL), with no statistically significant 
difference between the groups (p=0.460).
The serum levels of hepcidin in patients with Hepatitis 
C virus was of 8.4 pg/mL (± 4.94) vs. 19.5 (±5.51) in 
uninfected individuals with p<0.001. There was no 
statistically significant difference in the analysis of 
hepcidin-infected population levels in relation to sex, 
BMI (stratified as <25 and ≥25 and <30 kg/m2), viral 
load (stratified <600,000 IU/mL and ≥600,000 IU/mL), 
viral genotype (stratified on genotype 1 and non-1), 
levels of HOMA-IR (stratified as <2.71 and ≥2.71) and 
degrees of fibrosis METAVIR classification (stratified 
in fibrosis grade 0, 1, and 2) (Table 2). In both groups, 
the correlation between hepcidin and ferritin levels 
was not statistically significant: infected r=0.337, 
p=0.074 and uninfected r=0.275, p=0.475 (Figure 1). 
The relation between IL-6 and hepcidin level of the 
Table 1: Demographic data of patients chronically infected with Hepatitis C.
VARIABLE N (%) HEPCIDIN (pg/ml) p
SEX 29 (100) 0.803
MALE 16 (55) 8.18 (± 5.17)
FEMALE 13 (45) 8.66 (± 4.65)
BMI (kg/m2) 29 (100) 0.258
<25 17 (59) 9.2 (± 5.7)
≥25 and <30 12 (42) 7.1 (± 3.47)
HOMA-IR 27 (100) 0.727
<2.71 23 (85) 7.66 (± 4.01)
≥2.71 4 (15) 8.41 (± 3.27)
TOTAL CHOLESTEROL 
(mg/dl)
27 (100) 0.740
<200 24 (89) 8.73 (± 5.29)
≥200 3 (11) 7.71 (± 3.31)
TRYGLICERIDES (mg/dl) 29 (100) 0.684
<150 26 (89) 8.53 (± 5.29)
≥150 3 (11) 8.27 (± 3.31)
VIRAL GENOTYPE 29 (100) 0.550
GENOTYPE 1 19 (65) 8.8 (± 5.17)
GENOTYPE 2 AND 3 10 (35) 7.62 (± 4.05)
GENOTYPE 2 2 (7)
GENOTYPE 3 8 (28)
VIRAL LOAD (UI/ml) 23 (100) 0.610
<600.000 16 (70) 5.93 (± 2.08)
≥600.000 7 (30) 8.42 (± 3.89)
METAVIR 29 (100) 0.742
F0 8 (27.5) 7.21 (± 4.22)
F1 20 (69) 8.84 (± 5.35)
F2 1 (3.5) -
Figure 1: Correlation between hepcidin and ferritin levels. 
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infected group did not show a statistically significant 
relation (r=-0.17 p=0.440).
Former figure 1 was excluded due to irrelevant 
necessity.
DISCUSSION
This study attempted to reduce the confounding 
factors related to the expression of hepcidin, selecting 
infected and non-infected patients based on the 
exclusion of hepcidin expression modulating factors. 
This strategy aimed to assess the relationship of 
chronic infection by HCV and its influence on serum 
expression of hepcidin in the most reliable way. 
The selection of patients with low degrees of fibrosis 
(METAVIR) comes from the fact that patients with 
cirrhosis present a proinflammatory state with higher 
circulating levels of IL-6 leading to a higher hepcidin 
expression, as well as the obese, diabetic, alcoholic 
beverages users and those with chronic, neoplastic 
and/or infectious diseases.
We chose to study naïve patients to avoid any 
interference with the natural course of the infection. 
There was no difference in race, sex and BMI between 
the two groups, supporting the assertion that this 
is a homogeneous group, reducing the effect of 
any confounding factor. Regarding the lipid profile 
analyzed, the serum levels of total cholesterol and 
triglyceride groups, were similar, as were the values 
of HOMA–IR. In relation to the ferritin levels there was 
no statistically significant difference between the two 
groups, evidencing only a tendency to higher levels 
of ferritin in individuals with chronic hepatitis C virus 
infection. This finding may be related to the type II 
error (β) in the sample size and/or is a consequence 
of infected patient samples present only in early 
stages of liver fibrosis, thus suggesting shorter time 
of disease evolution and, consequently, lower levels 
of hepatic accumulation of iron. Regarding hepcidin, it 
became evident that the group chronically infected with 
HCV showed suppressed hormone levels compared 
Table 2: Group demographic data.
VARIABLE INFECTED (N=29) UNINFECTED (N=9) P
SEX 0.273
MALE 19 (55.2%) 7 (77.8%)
FEMALE 13 (45.8%) 2 (22.2%)
AGE (YEARS) 46.9 (± 7.07) 33.8 (± 5.2) < 0.001
COLOR (WHITE) 27 (93.1%) 9 (100%) 0.989
TOTAL CHOLESTEROL (mg/dl) 174.2 (± 36.9) 223.2 (± 48.2) 0303
TRYGLICERIDES (mg/dl) 92 (66.5-112.5) 125 (88-239) 0.074
HOMA-IR 1.74 (1.28-2.27) 1.48 (1.18-2.08) 0.72
FERRITIN 372.3 (± 132.4) 259.3 (± 67.3) 0.125
BMI (Kg/m2) 24.2 (± 2.42) 23.9 (± 2.48) 0.707
IL-6 33.8 (0.01-66.5) 41.6 (23.5-75) 0.460
to the uninfected group. This result confirms the 
theory that the hepatitis C virus per se modulates 
the expression of hepcidin directly influencing the 
iron recirculation mechanism and assisting in hepatic 
iron accumulation, increasing oxidative stress and 
thereby contributing to liver fibrogenesis as suggested 
in previous studies, both in animals and humans20-22. 
Girelli et al. examined the expression of serum 
hepcidin levels by specific ELISA, analyzing 57 
uninfected and 81 HCV patients. They demonstrated 
that hepcidin levels were significantly reduced in 
individuals carrying the virus22.
Nevertheless, this study included all degrees 
of fibrosis, and may have underestimated the true 
expression of hepcidin, since there is a lower mass 
of viable hepatocytes for the production of hepcidin 
and a higher accumulation of hepatic iron as well 
as a greater inflammatory process and IL-6, which 
may decrease the expression of hepcidin in cirrhotic 
livers with advanced fibrosis. Another study evaluated 
the levels of hepcidin in 27 patients before and after 
treatment for 48 weeks with PEG-interferon with ribavirin 
and demonstrated that prior to drug therapy, levels 
of hepcidin were reduced and after successful virus 
eradication, the levels of hepcidin increased21, thus 
reinforcing the theory that the virus is an independent 
factor for iron load. In relation to viral factors, such 
as viral genotype (segmented in genotype 1 and not 
1 (2 and 3)), and viral load values using the cut-off 
point ≤ 600.000 IU/mL as low, and values > 600.000 
IU/mL as high, no statistically significant differences 
were detected, suggesting that these factors are not 
related to the hepcidin expression, corroborating the 
data from previous studies21,22. In relation to IL-6 
serum levels, there were no significant differences 
between serum levels of hepcidin, in line with findings 
already described in the literature20,23.
Despite the small number of patients enrolled in 
this study, it was enough to show statistical power in 
correlating hepcidin and ferritin. Yet, our study has 
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